9.29
+0.57(+6.54%)
Currency In USD
| Previous Close | 8.72 |
| Open | 8.6 |
| Day High | 9.93 |
| Day Low | 8.6 |
| 52-Week High | 26.25 |
| 52-Week Low | 5.83 |
| Volume | 127,715 |
| Average Volume | 183,067 |
| Market Cap | 388.24M |
| PE | -0.78 |
| EPS | -11.89 |
| Moving Average 50 Days | 8.49 |
| Moving Average 200 Days | 11.86 |
| Change | 0.57 |
If you invested $1000 in ProShares UltraPro Short Nasdaq Biotechnology (ZBIO) since IPO date, it would be worth $516.97 as of May 09, 2025 at a share price of $9.29. Whereas If you bought $1000 worth of ProShares UltraPro Short Nasdaq Biotechnology (ZBIO) shares 0 years ago, it would be worth $516.97 as of May 09, 2025 at a share price of $9.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Apr 17, 2025 8:20 PM GMT
WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies
Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer
GlobeNewswire Inc.
Apr 07, 2025 11:05 AM GMT
Dr. Laken brings over 25 years of leadership experience in research, development operations, scientific assessment and strategyWALTHAM, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a cli
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
GlobeNewswire Inc.
Mar 17, 2025 11:05 AM GMT
–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) --